A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Phase 1 Completed 8 enrolled Kadmon, a Sanofi Company

RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.

Timeline

Start: 2014-03-28
Primary completion: 2014-06-07
Completion: 2014-06-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belumosudil	Small molecule	500 mg	Oral

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Summary

Timeline

Drugs

Indications